Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at politicsandmyportfolio.com, will continue to monitor these healthtech companies to see if the momentum continues. PoliticsAndMyPortfolio.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent JNJ Stock Price: $151.24
Summary: Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Josh Jennings analyst at TD Cowen reiterates coverage on Johnson & Johnson (JNJ) stock in the energy sector with a Buy rating and has set JNJ's stock price target at $195.
TipRanks.com reports that Johnson & Johnson currently has 4 analysts offering 12-month price targets on JNJ and the consensus is a Buy rating with an average stock price target of $179.50. The most recent JNJ stock price we have is $151.24 and we are not making any JNJ forecasts at this time.
In addition, TradingView issued a rating for JNJ over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on JNJ. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on JNJ, please click here >>
Jasper Therapeutics, Inc., JSPR
Recent JSPR Stock Price: $23.10
Summary: Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.
Yaron Werber analyst at TD Cowen reiterates coverage on Jasper Therapeutics, Inc. (JSPR) stock in the energy sector with a Buy rating and has not provided JSPR's stock price target.
TipRanks.com reports that Jasper Therapeutics, Inc. currently has 4 analysts offering 12-month price targets on JSPR and the consensus is a Buy rating with an average stock price target of $63.75. The most recent JSPR stock price we have is $23.10 and we are not making any JSPR forecasts at this time.
In addition, TradingView issued a rating for JSPR over the next month, Barchart.com has a buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on JSPR. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on JSPR, please click here >>
Larimar Therapeutics, Inc., LRMR
Recent LRMR Stock Price: $7.89
Summary: Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.
Jonathan Wolleben analyst at JMP Securities reiterates coverage on Larimar Therapeutics, Inc. (LRMR) stock in the energy sector with a Buy rating and has set LRMR's stock price target at $25.
TipRanks.com reports that Larimar Therapeutics, Inc. currently has 4 analysts offering 12-month price targets on LRMR and the consensus is a Buy rating with an average stock price target of $21.75. The most recent LRMR stock price we have is $7.89 and we are not making any LRMR forecasts at this time.
In addition, TradingView issued a rating for LRMR over the next month, Barchart.com has a buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on LRMR. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LRMR, please click here >>
Dyne Therapeutics, Inc., DYN
Recent DYN Stock Price: $32.63
Summary: Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.
Keay Nakae analyst at Chardan Capital reiterates coverage on Dyne Therapeutics, Inc. (DYN) stock in the energy sector with a Buy rating and has set DYN's stock price target at $42.
TipRanks.com reports that Dyne Therapeutics, Inc. currently has 4 analysts offering 12-month price targets on DYN and the consensus is a Buy rating with an average stock price target of $45.75. The most recent DYN stock price we have is $32.63 and we are not making any DYN forecasts at this time.
In addition, TradingView issued a rating for DYN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on DYN. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DYN, please click here >>
The editors at politicsandmyportfolio.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
PoliticsAndMyPortfolio.com keeps our subscribers informed of breaking news, reports, stock news or information that can have a positive or negative impact on their portfolio. We look at world events, political activity and the movement of stocks, bonds, metals, commodities and more to provide investors with timely information. Join thousands of investors who already signed up for our free subscription to PoliticsAndMyPortfolio.com.
==============================================================================
